Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers

Kazuo Okadome1, Yoshifumi Baba1,2, Daichi Nomoto1, Taisuke Yagi1, Rebecca Kalikawe1, Kazuto Harada1, Yukiharu Hiyoshi1, Yohei Nagai1, Takatsugu Ishimoto1, Masaaki Iwatsuki1, Shiro Iwagami1, Yuji Miyamoto1, Naoya Yoshida1, Masayuki Watanabe3, Yoshihiro Komohara4, Takashi Shono5, Yutaka Sasaki5 and Hideo Baba1

BACKGROUND
Oesophageal cancer is the sixth leading cause of cancer-related death and the seventh most common cancer worldwide. Despite the development of multimodal therapies, including surgery, chemotherapy and chemoradiotherapy, the prognosis of oesophageal cancer patients, including those who undergo complete resection, remains poor because of the extremely aggressive nature of this cancer type and the poor survival rate. The limited improvement in treatment outcome by conventional therapies has prompted the search for innovative strategies for the treatment of oesophageal cancer, especially immunotherapeutically targeted treatments.

The programmed death 1 (PD-1) pathway plays critical roles in tumour immunology, and serves as an immune-based therapeutic target. Less is known regarding PD-L2, another ligand of PD-1, and its relation to clinical outcome in human cancers.

METHODS: We used a database of 437 surgically and 100 endoscopically resected oesophageal cancers (squamous cell carcinoma, n = 483; adenocarcinoma, n = 36; others, n = 18) to evaluate PD-L2 and PD-L1 expression by immunohistochemistry.

RESULTS: Compared with PD-L2-negative cases (n = 366, 83.8%), PD-L2-positive cases (n = 71, 16.2%) had worse overall survival (P = 0.011, log-rank test). There was not a significant correlation between PD-L2 and PD-L1 expression. Multiplex immunofluorescence revealed that there was variability in the expression pattern of PD-L2 and PD-L1. In early-stage tumours, PD-L2 expression was more frequently observed compared with PD-L1.

CONCLUSIONS: PD-L2 as well as PD-L1 were associated with an unfavourable prognosis in oesophageal cancer, supporting the role of PD-L2 as a prognostic biomarker. Considering that PD-L2 and PD-L1 had different features in terms of expression timing and responses to chemotherapeutic drugs, evaluation of both PD-L2 and PD-L1 expression may be clinically important.

ARTICLE
Molecular Diagnostics

British Journal of Cancer (2020) 122:1535–1543; https://doi.org/10.1038/s41416-020-0811-0

© The Author(s), under exclusive licence to Cancer Research UK 2020
METHODS

Patients
A total of 495 consecutive patients with oesophageal cancer who were undergoing curative resection at Kumamoto University Hospital between April 2005 and March 2016 were enrolled in this study. Thirty-three patients who did not have assessable cancer cells were excluded, as well as 25 patients without clinical data. A total of 437 oesophageal cancer patients were finally included in this study. The most frequent histological type was squamous cell carcinoma (SCC, 383 patients, 87.6%), followed by adenocarcinoma (n = 36, 8.2%) and others (n = 18, 4.1%). There were 159 cases with preoperative chemotherapy or chemoradiotherapy. Most patients had received fluorouracil/cisplatin/docetaxel (n = 111, 69.8%) or fluorouracil/cisplatin (n = 39, 24.5%). Four cases had received other chemotherapeutic agents. In five cases, the regimen was unknown. Tumour stage was classified according to the eighth edition of the American Joint Committee on Cancer TNM classification system.23

Patients were followed up as outpatients every 1–3 months after discharge until death or December 2018. Overall survival was defined as the period from the date of surgery to the date of death. To evaluate the PD-L1 and PD-L2 expression status in early-stage cancer, we enrolled 100 patients with oesophageal squamous cell carcinoma, who underwent endoscopic submucosal dissection (ESD) at Kumamoto University Hospital. Among the ESD cases, 23 cases showed tumour depth of pT1a epithelium (EP) (= Tis), 22 cases were pT1a-lamina propria (LPM), 25 cases were pT1a–muscularis mucosae (MM) and 30 cases were pT1b submucosa (SM). No patient received chemotherapy or chemoradiotherapy before ESD treatment. Written informed consent was obtained from each subject, and the study procedures were approved by the Institutional Review Board of Kumamoto University. Throughout this paper, the term ‘prognostic marker’ is used according to REMARK Guidelines.24

PD-L1 and PD-L2 immunohistochemical staining
For PD-L2 staining, tumour sections (4 µm) were dewaxed and rehydrated, and antigen retrieval was performed by adding pH9 antigen retrieval solution (Histofine; Nichirei, Tokyo, Japan) and autoclavering at 121 °C for 15 min. After neutralisation of endogenous peroxidase, the sections were pre-incubated with blocking serum and incubated overnight at 4 °C with a primary antibody against PD-L2 (1:200, clone D7U8C, Cell Signaling Technology, MA, USA). The sections were incubated with biotinylated secondary antibodies and avidin–biotin complex method reagent (Vectastain Elite ABC Kit, Vector Laboratories, Burlingame, CA, USA). Mayer’s haematoxylin was used for counterstaining. We scored PD-L2 expression in tumour cells according to expression level (no expression = score 0, weak expression = score 1, moderate expression = score 2 or strong expression = score 3) (Supplementary Fig. 1a) and proportion of stained tumour cells (0–10% = score 0, 10–30% = score 1, 30–50% = score 2 or over 50% = score 3). The total score was calculated as the product of the expression and proportion score, and PD-L2-positive expression was determined as a score of 3 or more. PD-L1 staining and evaluation of PD-L1 expression were conducted as previously described (Supplementary Fig. 1b).37 PD-L1- and PD-L2-stained tissue sections were reviewed by two pathologists (Y.B. and Y.K.) who were unaware of other data.

Double immunohistochemical staining
Both PD-L1- and PD-L2-positive cases were subjected to double immunohistochemical staining. Briefly, immunohistochemical staining of PD-L2 and visualisation with DAB (Dako, Carpinteria, CA, USA) was performed as described above. After heating in a microwave at 600 W for 3 min, PD-L1 staining was then performed and visualised by HistoGreen (Cosmo Bio, Tokyo, Japan).

Multiple immunofluorescence
For multiplex immunohistochemical staining, anti-PD-L1, PD-L2 antibody described above and Opal 4-Color fluorescent IHC kit (PerkinElmer, Waltham, MA, USA) were used. PD-L1 was optimised using Opal 470 Fluorophore (red), and then PD-L2 was optimised using Opal 520 Fluorophore (green) according to the manual of the Opal IHC kit. Finally, VECTASHIELD mounting medium with DAPI (Vector) was used to stain nuclei.

Tumour-infiltrating lymphocyte evaluation
H&E-stained tissue sections were reviewed to assess tumour-infiltrating lymphocytes by a pathologist (Y.B.) who was unaware of other data. Lymphocyte infiltration in the tumour-invasive margin was scored as absent, mild, moderate or strong.

Quantitative real-time reverse transcription–polymerase chain reaction
Twenty-five pairs of primary oesophageal squamous cell carcinoma tissues and matched oesophageal epithelia were obtained from resected oesophageal cancer patients to evaluate PD-L2 expression. Total RNA was isolated from tissue samples using an RNasey Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer’s protocol. The mRNA expression levels were determined by quantitative real-time reverse transcription–polymerase chain reaction (qRT–PCR) using TaqMan probes (Roche, Basel, Switzerland), and were normalised to those of β-actin. To design the qRT–PCR primers, we accessed the Universal Probe Library (Genenet, Fukuoka, Japan), following the manufacturer’s recommendations. Real-time PCR was performed with the following primer sequences and probes: PD-L2 (PD-L2_#36), 5′–AAAGAGGGAAGTGAACAGTGC T-3′ and 5′–GCTTCTTTCAGATGTGATACAGGCTCA-3′, and β-actin (ACTB_811), 5′–ATTGGCAATGACGGTTC-3′ and 5′–CGTTGATGGCACCAGACT-3′. All qRT–PCR reactions were performed in the LightCycler 480 System II (Roche). All data for qRT–PCR were obtained from triplicate experiments, and are presented as the mean ± standard error.

Statistical analysis
All statistical calculations were performed with JMP version 13 software (SAS Institute, Cary, NC, USA). All P values were two-sided. Categorical variables were presented as numbers and percentages, and groups were compared using the χ2 test or Fisher’s exact test. Continuous variables were expressed as means and standard deviations, and means were compared using the t test. The survival time distribution was evaluated by the Kaplan–Meier method, and the log-rank test was used for comparisons. Variables for which the P value in the univariate analysis was <0.05 were subjected to multivariate analysis by a stepwise backward elimination procedure using a threshold P value of <0.05. P < 0.05 was considered statistically significant.

RESULTS

PD-L2 expression in oesophageal cancer patients
We evaluated the expression level of PD-L2 mRNA by qRT–PCR in 25 oesophageal cancer tissues, and matched normal oesophageal epithelium. PD-L2 expression in oesophageal cancer was significantly higher than that in normal oesophageal epithelium (P = 0.048) (Fig. 1a). In the PD-L2-positive cases confirmed by immunohistochemical staining, PD-L2 expression was elevated in cancer cells compared with normal oesophageal epithelium (Supplementary Fig. 1c). Tumour samples from the 437 oesophageal cancer cases included in this study were examined for PD-L2 expression by immunohistochemistry, and scored as described in ‘Methods’. Among the 437 cases, 71 (16.2%) were in the PD-L2-positive group, and 366 (83.8%) were in the PD-L2-negative group. Representative immunohistochemical staining is shown in Fig. 1b.
Among the 437 oesophageal cancer patients, 152 deaths occurred, including 95 oesophageal cancer-specific deaths, and 135 recurrences of oesophageal cancer were observed. The median follow-up time of censored patients was 4.4 years. Kaplan–Meier analysis indicated that the PD-L2-positive group had significantly shorter overall survival (P = 0.011, log-rank test) than the PD-L2-negative group. The 3-year overall survival rate was 62.1% in the PD-L2-positive group, and 71.5% in the PD-L2-negative group. In the univariate Cox regression analyses, patients in the PD-L2-positive group showed significantly higher overall mortality than those in the PD-L2-negative group [hazard ratio (HR): 1.63; 95% confidence interval (CI): 1.09–2.36; P = 0.018]. Adjusting for clinical, epidemiological and pathological features in the multivariate Cox model, PD-L2 was associated with significantly higher overall mortality (multivariate HR: 1.81; 95% CI: 1.21–2.63; P = 0.004) (Table 1). We also employed an additional multivariate Cox model including PD-L1, and found that PD-L2 expression was an independent prognostic factor (multivariate HR: 1.75; 95% CI: 1.17–2.55; P = 0.007). We next determined whether the influence of PD-L2 on overall survival was affected by clinical, pathological or epidemiological variables. The effect of PD-L2 was not significantly modified by age, sex, tobacco use, comorbidity, location, pathological stage or recurrence (P > 0.14 for all interactions) (Fig. 1d).

**PD-L2 expression and patient survival**

Among the 437 oesophageal cancer patients, 152 deaths occurred, including 95 oesophageal cancer-specific deaths, and 135 recurrences of oesophageal cancer were observed. The median follow-up time of censored patients was 4.4 years. Kaplan–Meier analysis indicated that the PD-L2-positive group had significantly shorter overall survival (P = 0.011, log-rank test) than the PD-L2-negative group (Fig. 1c). The 3-year overall survival rate was 62.1% in the PD-L2-positive group, and 71.5% in the PD-L2-negative group. In the univariate Cox regression analyses, patients in the PD-L2-positive group showed significantly higher overall mortality than those in the PD-L2-negative group [hazard ratio (HR): 1.63; 95% confidence interval (CI): 1.09–2.36; P = 0.018]. Adjusting for clinical, epidemiological and pathological features in the multivariate Cox model, PD-L2 was associated with significantly higher overall mortality (multivariate HR: 1.81; 95% CI: 1.21–2.63; P = 0.004) (Table 1). We also employed an additional multivariate Cox model including PD-L1, and found that PD-L2 expression was an independent prognostic factor (multivariate HR: 1.75; 95% CI: 1.17–2.55; P = 0.007). We next determined whether the influence of PD-L2 on overall survival was affected by clinical, pathological or epidemiological variables. The effect of PD-L2 was not significantly modified by age, sex, tobacco use, comorbidity, location, pathological stage or recurrence (P > 0.14 for all interactions) (Fig. 1d).

**Fig. 1** PD-L2 expression in oesophageal cancer and association with patient survival. a qRT–PCR analysis of PD-L2 mRNA expression in 25 oesophageal cancer samples of matched normal epithelium and cancer. High PD-L2 expression was observed in the tumour part compared with normal epithelium (P = 0.048). b Immunohistochemistry of PD-L2 expression in oesophageal cancer tumour sections. In PD-L2-positive cases, PD-L2 was stained in the cytoplasm and/or membrane of cancer cells. Original magnification, ×200. c Kaplan–Meier curves for overall survival in oesophageal cancer patients according to PD-L2 expression status. The PD-L2-positive group showed a significantly shorter overall survival than the PD-L2-negative group (log-rank P = 0.011). d Relationship between PD-L2 and overall survival. Loge (hazard ratio) plots of overall survival rate in PD-L2-positive and PD-L2-negative groups are shown. The effect of PD-L2 was not significantly modified by age, sex, tobacco, comorbidity, location, pathological stage or recurrence (P > 0.14 for all interactions).
Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort. We previously reported that PD-L1 expression was associated with pathological stage (multivariate OR: 0.59; 95% CI: 0.36–0.95; P = 0.030), and tumour-infiltrating lymphocytes (multivariate OR: 0.62; 95% CI: 0.38–0.99; P = 0.048) were significantly associated with both PD-L1- and PD-L2-negative groups. These findings indicate the need to evaluate not only PD-L1 but also PD-L2 expression in oesophageal cancers.

Differences in timing of PD-L1 and PD-L2 expression during tumour development

As previously indicated, PD-L1 expression was significantly associated with pathological stage (P = 0.001) and tumour depth (P = 0.013) (Fig. 3a), and frequently observed in advanced-stage tumours. In contrast, no relationship was observed between PD-L2 expression and pathological stage (P = 0.94); PD-L2 positivity was observed in both early- and advanced-stage tumours. Based on these findings, we hypothesised that there may be a difference in emergence of PD-L2 and PD-L1 expression during tumour development to test this hypothesis, we examined the frequency of PD-L2 and PD-L1 positivity in 100 ESD cases with early-stage tumours because ESD is often performed for cases with superficial oesophageal cancer without metastasis in Japan.25,26 Out of 100 cases, 27 (27%) cases were PD-L2 positive and 18 (18%) cases were PD-L1 positive. In the ESD samples, there was no significant relationship between PD-L2 and PD-L1 expression (P = 0.21) (Fig. 3b). A representative case is shown in Fig. 3c. In early-stage cases, the frequency of PD-L1-positive cases increased as the tumour progressed in depth, but PD-L2 did not have a relation with the depth; dividing cases into pT1a and pT1b cases by depth revealed that the positive rates of PD-L1 and PD-L2 were 10% and 25.7% for pT1a, and 36.7% and 30% for pT1b, respectively (Fig. 3d). In comparing the immunohistochemistry score, the expression of PD-L2 was significantly higher than PD-L1 (P = 0.038), with an average of 0.86 for PD-L1 and 1.57 for PD-L2 in pT1a (Fig. 3e). There was no significant difference in scores among pT1b cases (2.57 and 1.63, respectively) (P = 0.18).

Table 1. Univariate and multivariate analysis of overall survival.

| Variables | Univariate analysis | | Multivariate analysis |
|-----------|---------------------|---|---------------------|
|           | HR (95% CI)         | P | HR (95% CI)         | P |
| Age (≥65 vs. <65) | 1.38 (0.99–1.93) | 0.097 | 1.48 (1.00–2.23) | 0.048 |
| Sex (male vs. female) | 1.37 (0.81–2.54) | 0.61 | 1.33 (0.82–1.98) | 0.13 |
| Tobacco use (yes vs. no) | 0.97 (0.67–1.53) | 0.12 | 1.33 (0.82–2.0) | 0.13 |
| Body mass index (<22 vs. ≥22) | 1.17 (0.85–1.63) | 0.94 | 1.20 (0.78–1.80) | 0.39 |
| Comorbidity (present vs. absent) | 1.33 (0.92–1.98) | 0.13 | 1.20 (0.78–1.80) | 0.39 |
| Location (upper vs. middle and lower) | 1.20 (0.78–1.80) | 0.39 | 2.36 (1.09–5.83) | 0.018 |
| Pathological stage (II–IV vs. I) | 2.53 (1.77–3.71) | <0.001 | 4.41 (3.10–6.33) | <0.001 |
| Recurrence (present vs. absent) | 4.88 (3.51–6.83) | <0.001 | 1.17 (0.81–1.67) | 0.39 |
| Adjuvant therapy (present vs. absent) | 1.63 (1.09–2.36) | 0.018 | 1.81 (1.21–2.63) | 0.004 |
| PD-L2 (positive vs. negative) | | | |

HR hazard ratio, CI confidence interval, PD-L2 programmed death ligand 2.
The influence of preoperative therapy on PD-L1 and PD-L2 expression

Clinical data showed that PD-L1-positive cases were significantly associated with preoperative therapy-treated cases ($P = 0.015$), while PD-L2-positive cases did not show this association ($P = 0.81$).

We further examined the positive rate of PD-L1 and PD-L2 in the no preoperative therapy group, preoperative chemotherapy group and preoperative chemoradiotherapy group (Supplementary Fig. 1d). The positive rate of PD-L1 was higher in patients who received preoperative chemotherapy (21.8%; $P = 0.023$) or chemoradiotherapy (20.4%; $P = 0.143$) than in patients who did not receive preoperative therapy (12.6%). The positive rate of PD-L2
was not significantly altered in these groups (16.6%, 17.3% and 12.2%, respectively). To clearly assess the effect of chemotherapy on PD-L2 expression, we examined pre-treatment status of PD-L2 expression using biopsy samples. However, the PD-L2 expression status in resected and biopsy specimens does not necessarily correlate (data not shown). This might be due to the heterogeneity of PD-L1/L2 expression in tumours.

**DISCUSSION**

In this study, we evaluated PD-L2 as well as PD-L1 expression by immunohistochemistry in more than 400 patients with surgically resected oesophageal cancer, and examined the prognostic impacts of PD-L1 and PD-L2 expressions in oesophageal cancer. PD-L2 and PD-L1 expression was associated with an unfavourable clinical outcome of oesophageal cancer, suggesting that the PD-L2 expression status may serve as a biomarker to identify patients who are likely to experience an unfavourable clinical outcome. In addition, this is the first study to assess the prognostic features of the combination of PD-L2 and PD-L1 statuses in more than 400 patients with surgically resected oesophageal cancer. We also found that PD-L2 and PD-L1 showed different expression timings during tumour development, and various responses to chemotherapy agents. Considering that immunotherapies, such as immune checkpoint inhibitors, have gained increasing attention as a novel treatment strategy for oesophageal cancer, our observations may have clinical implications.

The importance of PD-L1 expression as a predictive and prognostic biomarker in human cancers has been well studied. Nonetheless, PD-L2, another ligand of PD-1, has gained less attention. Whether PD-L2 expression correlates with prognosis in solid cancer patients after surgery remains elusive. With regard to oesophageal cancer patients, some papers reported that high PD-L2 expression in oesophageal cancer was associated with

| Variables                          | PD-L1 | PD-L2 |
|-----------------------------------|-------|-------|
|                                   | Negative N = 366 | Positive N = 69 | P value | Negative N = 366 | Positive N = 71 | P value |
| Age (y), mean ± SD                | 65.9 ± 9.0 | 67.4 ± 9.0 | 0.90 | 66.5 ± 9.0 | 64.3 ± 8.8 | 0.029 |
| Sex                               | 0.39 |       |
| Male                              | 328 (89.1) | 59 (85.5) |       | 323 (88.3) | 64 (90.1) |       |
| Female                            | 40 (10.9) | 10 (14.5) |       | 43 (11.8) | 7 (9.9) |       |
| Body mass index, mean ± SD        | 21.8 ± 3.0 | 21.5 ± 3.3 | 0.50 | 21.7 ± 3.1 | 21.8 ± 3.1 | 0.72 |
| Tobacco use                       | 0.113 |       |
| Yes                               | 316 (85.9) | 51 (73.9) |       | 305 (83.3) | 62 (87.3) |       |
| No                                | 52 (14.1) | 18 (26.1) |       | 61 (16.7) | 9 (12.7) |       |
| Alcohol use                       | 0.01 |       |
| Yes                               | 325 (88.3) | 56 (81.2) |       | 321 (87.7) | 60 (84.5) |       |
| No                                | 43 (11.7) | 13 (18.8) |       | 45 (12.3) | 11 (15.5) |       |
| Comorbidity                       | 0.23 |       |
| Present                           | 262 (71.2) | 54 (78.3) |       | 266 (72.7) | 50 (70.4) |       |
| Absent                            | 106 (28.8) | 15 (21.7) |       | 10 (27.3) | 21 (29.6) |       |
| Histological type                 | 0.32 |       |
| Squamous cell carcinoma           | 319 (86.7) | 64 (92.8) |       | 322 (88.0) | 61 (85.9) |       |
| Adenocarcinoma                    | 32 (8.7) | 4 (5.8) |       | 29 (7.9) | 7 (9.9) |       |
| Others                            | 17 (4.6) | 1 (1.5) |       | 15 (4.1) | 3 (4.2) |       |
| Location                          | 0.64 |       |
| Upper                             | 59 (16.0) | 8 (11.6) |       | 54 (14.8) | 13 (18.3) |       |
| Middle                            | 171 (46.5) | 34 (49.3) |       | 168 (45.9) | 37 (51.2) |       |
| Lower                             | 138 (37.5) | 27 (39.1) |       | 144 (39.3) | 21 (29.6) |       |
| pStage                            | 0.001 |       |
| I                                 | 159 (43.2) | 14 (20.3) |       | 145 (39.6) | 28 (39.4) |       |
| II                                | 97 (26.4) | 19 (27.5) |       | 99 (27.1) | 17 (23.9) |       |
| III                               | 10 (27.2) | 32 (46.4) |       | 109 (29.8) | 23 (32.4) |       |
| IV                                | 12 (3.3) | 4 (5.8) |       | 13 (3.6) | 3 (4.2) |       |
| Preoperative therapy              | 0.015 |       |
| Present                           | 125 (34.0) | 34 (49.3) |       | 134 (36.6) | 25 (35.2) |       |
| Absent                            | 243 (66.0) | 35 (50.7) |       | 232 (63.4) | 46 (64.8) |       |
| Tumour-infiltrating lymphocytes (at the invasive margin) | 0.030 |       |
| Absent                            | 8 (2.2) | 0 (0) |       | 7 (1.9) | 1 (1.4) |       |
| Mild                              | 121 (32.9) | 18 (26.1) |       | 119 (32.5) | 20 (28.2) |       |
| Moderate                          | 171 (46.5) | 28 (40.6) |       | 169 (46.2) | 30 (42.3) |       |
| Strong                            | 68 (18.5) | 23 (33.3) |       | 71 (19.4) | 20 (28.2) |       |

_PD-L1 programmed death ligand 1, PD-L2 programmed death ligand 2._

was not significantly altered in these groups (16.6%, 17.3% and 12.2%, respectively). To clearly assess the effect of chemotherapy on PD-L2 expression, we examined pre-treatment status of PD-L2 expression using biopsy samples. However, the PD-L2 expression status in resected and biopsy specimens does not necessarily correlate (data not shown). This might be due to the heterogeneity of PD-L1/L2 expression in tumours.
impaired survival,18,19 and another study showed no correlation between PD-L2 and clinical outcome.20 However, all of these studies were limited by small sample sizes (n ≤ 180) and low statistical power. In contrast to previous studies, our study evaluated PD-L2 expression by immunohistochemistry in a much larger cohort of oesophageal cancers.

Both PD-L2 and PD-L1 are B7 family members, and binding of these ligands to the receptor PD-1 results in inhibition of T- and B-cell responses.6 Although there are many similarities between PD-L2 and PD-L1, some differences have been reported in regard to localisation,8 receptors,27 affinity with their receptor PD-121,22 and response to cytokines.28 The relationship between PD-L1 and PD-L2 expression in various types of cancers is still controversial.29–32 In this study, our results showed no significant relationship between PD-L1 and PD-L2 expression in oesophageal cancer. In addition, our multiple immunohistochemical staining and multiplex immunofluorescence showed the heterogeneity of PD-L1 and PD-L2 expression. Cancer cells with only PD-L2 expression and those with only PD-L1 expression exist simultaneously in tumours with both PD-L2- and PD-L1-positive cases. We thus speculate that PD-L2 might exhibit different functions than PD-L1 in oesophageal cancer development and progression.

Simultaneous assessment of not only PD-L1 but also PD-L2 for the therapeutic effect of immune checkpoint inhibitors may be clinically important. Yearley et al.33 reported that PD-L2 status was a significant predictor of progression-free survival with pembrolizumab independent of PD-L1 status, and the objective response rate was the highest in patients expressing both PD-L1 and PD-L2 in head and neck squamous cell carcinoma cases. Simultaneous evaluation of PD-L2 along with PD-L1 may result in an increased number of patients indicated for PD-1/PD-L1 signal-blockade agents; these drugs may yield positive results in patients negative

Fig. 3 Examination of PD-L1 and PD-L2 expression in early-stage patients using ESD samples. a PD-L1 expression was significantly associated with tumour depth (P = 0.003), and no relationship was observed between PD-L2 expression and tumour depth (P = 0.19) in surgically resected samples. b The relationship between PD-L1 and PD-L2 expression status in ESD samples. There was no significant correlation between PD-L1 and PD-L2 expression (P = 0.21) (n = 100). c PD-L1-negative and PD-L2-positive expression in early-stage oesophageal cancer patients with ESD samples. Original magnification, x100. d The positive rate of PD-L1 and PD-L2 for T1a and T1b tumour depth in 100 ESD samples. The positive rates of PD-L1 and PD-L2 were 10% and 25.7% for pT1a, and 36.7% and 30% for pT1b, respectively. e The relationship between immunohistochemistry (IHC) score of PD-L1/L2 and tumour depth. The IHC score was calculated as the product of the expression and proportion scores.
for PD-L1 and positive for PD-L2. In this study, the assessment of the combination of PD-L2 and PD-L1 could enable further classification of patients according to clinical outcome. Our results revealed two differences between PD-L1 and PD-L2 expression in oesophageal cancers. One is the relationship between PD-L1 and PD-L2 expression and tumour stage. PD-L1 expression may increase along with tumour progression, while PD-L2 expression occurred relatively earlier compared with PD-L1. Another observation from our results is the relationship between PD-L1, PD-L2 and chemotherapy. Recently, the precise strategy for administering chemotherapy and immune checkpoint inhibitor in combination or sequentially has been debated.34–36 Our clinical data demonstrate that preoperative treatment is associated with PD-L1 expression, but not PD-L2 expression. Although PD-L1 expression is known to be upregulated due to various chemotherapeutic drugs or radiation therapies,37–42 only one report has examined the effect of these treatments on PD-L2 expression, (Supplementary Table 2). A better understanding of the influence of chemotherapeutic drugs on PD-L1 and PD-L2 expression may enable more accurate prediction of the treatment effect of immune checkpoint inhibitors.

In summary, our large cohort study, including more than 400 cases, revealed that PD-L2 expression, as well as PD-L1, was associated with an unfavourable clinical outcome in oesophageal cancer, supporting the role of PD-L2 as a prognostic biomarker. In addition, we found that PD-L2 and PD-L1 presented different features in terms of the expression timing and the response to chemotherapeutic drugs. Considering that drugs targeting the PD-1 pathway are being intensively developed and tested in clinical trials for various human cancers, PD-L1 and PD-L2 expression in oesophageal cancer may serve as a predictive biomarker, and may be used for patient selection in clinical trials of such drugs.

ACKNOWLEDGEMENTS

We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this paper.

AUTHOR CONTRIBUTIONS

K.O., Y.B., T.I., Y.S. and H.B. designed experiments and conceptions. K.O., Y.B., D.N., T.Y., K.O., Y.B., T.I., Y.S. and H.B. drafted the paper. B.T., Y.J. and S.J. critically revised the paper for important intellectual contents. All authors finally approved the paper.

ADDITIONAL INFORMATION

Ethics approval and consent to participate This study was approved by the Institutional review Board of Kumamoto University (Permit number: 1365). Written informed consent was obtained from each patient. Our study was performed in accordance with the Declaration of Helsinki.

Data availability The datasets used and/or analysed during this study are available from the corresponding author on reasonable request.

Competing interests The authors declare no competing interests.

Funding information JSPS KAKENHI, grant number 17H04273, 17K19702 and 17KO1915 (to Y.B.).

Supplementary information is available for this paper at https://doi.org/10.1038/s41416-020-0811-0.

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
2. Smyth E. C., Lagergren J., Fitzgerald R. C., Lordick F., Shah M. A., Lagergren P. et al. Oesophageal cancer. Nat. Rev. Dis. Primers https://doi.org/10.1038/nrdp.2017.48 (2017).
3. Yang, H., Liu, H., Chen, Y., Zhu, C., Fang, W., Yu, Z. et al. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): a phase III Multi-center, Randomized, Open-Label Clinical Trial. J. Clin. Oncol. 36, 2796–2803 (2018).
4. Wang, V. E., Grandis, J. R. & Ko, A. H. New strategies in esophageal carcinoma: translational insights from signaling pathways and immune checkpoints. Clin. Cancer Res. 22, 4283–4290 (2016).
5. Harada, K., Mizra, Kaya, D., Baha, H. & Ajani, J. A. Immune checkpoint blockade therapy for esophageal squamous cell carcinoma. J. Thorac. Dis. 10, 699–702 (2018).
6. Freeman, G. J., Long, A. A., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).
7. Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261–268 (2001).
8. Tseng, S. Y., Otsuji, M., Gorski, K., Huang, X., Slansky, J. E., Pai, S. I. et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193, 839–846 (2001).
9. Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
10. Reck, M., Rodriguez-Arue, D., Robinson, A. G., Hui, R., Cossio, T., Fulop, A. et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
11. Wolchok, J. D., Chariot-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Cowey, C. L. et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).
12. Kudo, T., Hamamoto, Y., Kato, K., Ura, T., Kojima, T., Tsushima, T. et al. Nivolumab treatment for esophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 18, 631–639 (2017).
13. Janjigian, Y. A., Bennell, J., Calvo, E. & Kim, J. W. CheckMate-032 Study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophageal cancer. J. Clin. Oncol. 36, 2836–2844 (2018).
14. Topalian, Suzanne, L., Drake Charles, G. & Pardoll, Drew M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015).
15. Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847–856 (2015).
16. Wang, X., Teng, F., Kong, L. & Yu, J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 9, 5023–5039 (2016).
17. Yagi, T., Baba, Y., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N. et al. PD-L1 expression, tumor-infiltrating lymphocytes, and clinical outcome in patients with surgically resected esophageal cancer. Ann. Surg. 269, 471–478 (2019).
18. Ohigashi, Y., Shn, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N. et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res 11, 2947–2953 (2005).
19. Tanaka, K., Miyata, H., Sugimura, K., Kanemura, T., Hamada-Uematsu, M., Mizote, Y. et al. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. Cancer Sci. 107, 726–733 (2016).
20. Leng, C., Li, Y., Qin, J., Ma, J., Liu, X., Cui, Y. et al. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8(+) T cells. Oncol. Rep. 35, 699–708 (2016).
21. Youngnak, P., Kozono, Y., Kozono, H., Iwai, H., Otsuki, N., Jin, H. et al. Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys. Res. Commun. 307, 672–677 (2003).
22. Cheng, X., Veverka, V., Radhakrishnan, A., Waters, L. C., Muskett, F. W., Morgan, S. H. et al. Structure and interactions of the human programmed cell death 1 receptor. J. Biol. Chem. 288, 11771–11785 (2013).
23. Rice, T. W., Patil, D. T. & Blackstone, E. H. 8th edition AJCC/UICC staging of cancers of the esophagus and esophageo-gastric junction: application to clinical practice. Ann. Cardiothorac. Surg. 6, 119–130 (2017).
24. McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., Clark, G. M. et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 97, 1180–1184 (2005).
25. Oyama, T., Tomori, A., Hotta, K., Morita, S., Kominato, K., Tanaka, M. et al. Endoscopic submucosal dissection of early esophageal cancer. *Clin. Gastroenterol. Hepatol.* 3, S67–S70 (2005).

26. Balmadrid, B. & Hwang, J. H. Endoscopic resection of gastric and esophageal cancer. *Gastroenterol. Rep.* 3, 330–338 (2015).

27. Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H. & Freeman, G. J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. *Immunity* 27, 111–122 (2007).

28. Loke, P. & Allison, J. P. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. *Proc. Natl Acad. Sci. USA* 100, 5336–5341 (2003).

29. Konishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H. & Nishimura, M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. *Clin. Cancer Res.* 10, 5094–5100 (2004).

30. Koh, J., Go, H., Keam, B., Kim, M. Y., Nam, S. J., Kim, T. M. et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. *Mod. Pathol.* 28, 1154–1166 (2015).

31. Kim, M. Y., Koh, J., Kim, S., Go, H., Jeon, Y. K. & Chung, D. H. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. *Lung Cancer* 88, 24–33 (2015).

32. Inoue, Y., Yoshimura, K., Mori, K., Kurabe, N., Kahyo, T., Mori, H. et al. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. *Oncotarget* 7, 32113–32128 (2016).

33. Yearley, J. H., Gibson, C., Yu, N., Moon, C., Murphy, E., Jucov, J. et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. *Clin. Cancer Res.* 23, 3158–3167 (2017).

34. Wu, Y., Shi, H., Jiang, M., Qiu, M., Jia, K., Cao, T. et al. The clinical value of combination of immune checkpoint inhibitors in cancer patients: a meta-analysis of efficacy and safety. *Int. J. Cancer* 141, 2562–2570 (2017).

35. Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N. Engl. J. Med.* 378, 2078–2092 (2018).

36. Luo, Q., Zhang, L., Luo, C. & Jiang, M. Emerging strategies in cancer therapy combining chemotherapy with immunotherapy. *Cancer Lett.* 454, 191–203 (2019).

37. Van Der Kraak, L., Goel, G., Ramanan, K., Kaltenmeier, C., Zhang, L., Normolle, D. P. et al. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. *J. Immunother. Cancer* https://doi.org/10.1186/s40425-016-0163-8 (2016).

38. Ock, C. Y., Kim, S., Keam, B., Kim, S., Ahn, Y. O., Chung, E. J. et al. Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. *Oncotarget* 8, 97920–97927 (2017).

39. Zhang, P., Su, D. M., Liang, M. & Fu, J. Chemopreventive agents induce programmed death-1-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. *Oncotarget* 8, 97920–97927 (2017).

40. Chaganty, B. K. R., Qiu, S., Gest, A., Lu, Y., Ivan, C., Calin, G. A. et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNgamma secretion. *Cancer Lett.* 430, 47–56 (2018).

41. Liu, X. D., Hoang, A., Zhou, L., Kalra, S., Yetil, A., Sun, M. et al. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. *Cancer Immunol. Res.* 3, 1017–1029 (2015).

42. Derer A., Spiljar M., Baumler M., Hecht M., Fietkau R., Frey B. et al. Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells. *Front. Immunol.* https://doi.org/10.3389/fimmu.2016.00610 (2016).

43. Lesterhuis, W. J., Punt, C. J., Hato, S. V., Eleveld-Trancikova, D., Jansen, B. J., Nierkens, S. et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. *J. Clin. Invest.* 121, 3100–3108 (2011).